Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1538-1546

  Arranz, Reyes ^a   García Alfonso, Pilar ^a   Sobrino, Paz ^a   Zamora, Pilar ^a   Carrión, Rafael ^a   García Laraña, José ^a   Pérez, Guillermo ^a   López, Javier ^a   Lavilla, Esperanza ^a   Lozano, Matilde ^a   Rayón, Consuelo ^a   Colomer, Ramón ^a   González Barón, Manuel ^a   Flores, Eduardo ^a   Pérez Manga, Gumersindo ^a   Fernández Rañada, José M ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CYCLOPHOSPHAMIDE; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0344157390     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1538     Document Type: Article

References (36)

1. Merigan TC, Sikora K, Breeden JH, et al: Preliminary observation on the effect of human leucocyte interferon in non-Hodgkin's lymphoma. N Engl J Med 299:1449-1453, 1978
2. Loiuie AC, Gallagher JG, Sikora K: Follow-up observations on the effect of human leucocyte interferon in non-Hodgkin's lymphoma. Blood 58:712-718, 1981
3. Gutterman JV, Blumenschein GR, Alexanian R, et al: Leucocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 93:399-406, 1980
4. O'Connell MJ, Colgan JP, Oken MM, et al: Clinical trial of recombinant leucocyte interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group Pilot study. J Clin Oncol 4:128-136, 1986
5. Foon KA, Sherwin SA, Abrans PG, et al: Treatment of advanced non-Hodgkin's lymphoma with recombinant leucocyte interferon. N Engl J Med 311:1148-1152, 1984
6. Quesada JR, Hawkins M, Hormi S, et al: Collaborated phase I-II study of recombinant DNA-produced leucocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Am J Med 77:427-432, 1984
7. Balkwill FR, Moodie EM: Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res 44:904-908, 1984
8. Gresser I, Manry C, Tovey M: Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. Eur J Cancer 14:97-99, 1978
9. Chisesi T, Congin M, Contu A, et al: Randomized study of chlorambucil (CB) compared to interferon (alfa 2-b) combined with CB in low-grade non-Hodgkin's lymphoma: An interim report of a randomized study. Eur J Cancer 27:31-33, 1991
10. Pangalis GA, Tsekouras CH, Bonssiotis VA, et al: Treatment of low-grade non-Hodgkin's lymphomas with chlorabucil and interferon alpha-2b. Fifth International Conference on Malignant Lymphoma. Lugano, Switzerland, June 9-12, 1993 (abstr 154), p 149
11. Smalley RV, Andersen JW, Hawkins MJ, et al: Interferon-alfa combined cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327:1336-1341, 1992
12. Solal-Celigny P, Lepage E, Brousse N, et al: Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 329:1608-1614, 1993
13. McLaughin P, Cabanillas F, Hagemeister FB, et al: CHOP-B plus interferon in the treatment of stage IV low-grade lymphoma. Ann Oncol 5:421-428, 1993
14. Hagenbeek A, Carde P, Somers R, et al: On the influence of human recombinant alpha-2 interferon on remission duration in patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. Results from a prospective, randomized phase III clinical trial in 346 patients. Fifth International Conference on malignant lymphoma, Lugano, Switzerland, June 9-12, 1993 (abstr 66), p 54
15. Hiddeman W, Unterhalt M, Koch P, et al: Alfa-interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphoma after cytoreductive chemotherapy with prednimustine and mitoxantrone. Eur J Cancer 27:37-39, 1991
16. Peterson BA, Petroni GR, Oken MM, et al: Cyclophosphamide versus cyclophosphamide plus interferon alpha-2b in follicular low-grade lymphomas: An intergroup phase III trial (CALB 8691 and EST 7486). Proc Am Soc Clin Oncol 16:14a, 1997 (abstr)
17. Price CG, Rohatiner AZ, Steward W, et al: Interferon alfa-2b in the treatment of follicular lymphoma: Preliminary results of a trial in progress. Ann Oncol 2:141-145, 1991
18. National Cancer Institute Sponsored Study of Classification of Non-Hodgkin's Lymphomas: Summary and description of a Working Formulation for clinical usage. The non-Hodgkin's lymphoma pathologic classification project. Cancer 49:2112-2135, 1982
19. Zubrod CG, Scheiderman M, Frei E, et al: Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutical trial of nitrogen mustard and methylene thiophosphoramide. J Chron Dis 11:7-33, 1960
20. Bagley CM, DeVita VT, Berard CW, et al: Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med 76:227-234, 1972
21. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
22. Longo DL, Duffey PL, DeVita V, et al: The calculation of actual dose intensity: A comparison of published methods. J Clin Oncol 9:2042-2051, 1991
23. Armitage P, Berry G: Statistical Methods in Medical Research (ed 2). Oxford, England, Blackwell Scientific, 1987
24. Parmar MKB, Machin D: Survival Analysis: A practical Approach. Medical Research Council Center Trials Office. Cambridge, UK, Wiley, 1995
25. Burman P, Tötterman TH, Öberg K, et al: Thyroid autoimmunity in patients on long-term therapy with leukocyte-derived Interferon. J Clin Endocrinol Metab 63:1086-1090, 1986
26. Kennedy BJ, Bloomfield CD, Kiang DT, et al: Combination versus successive single-agent chemotherapy in lymphocytic lymphoma. Cancer 41:23-28, 1978
27. Hoppe RT, Kushlan P, Kaplan HS, et al: The treatment of advanced-stage favorable histology non-Hodgkin's lymphoma: A preliminary report of a randomized trial comparing single-agent chemotherapy, combination chemotherapy, and whole-body irradiation. Blood 58:592-598, 1981
28. Steward WP,Crowther D,McWilliam LJ, et al: Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. Cancer 61:441-447, 1988
29. De Maeyer E, De Maeyer-Guignar J: From an antiviral factor to a family of multifunctional cytokines, In De Maeyer E, De Maeyer-Guignar J (eds): Interferons and Other Regulatory Cytokines. New York, NY, Wiley, 1988, pp 1-4
30. Andersen JW, Smalley RV: Interferon-alfa plus chemotherapy for non-Hodgkin's lymphoma: Five-year follow-up. N Engl J Med 329:1821-1822, 1993 (letter)
31. Avilés A, Duque G, Talavera A, et al: Interferon alfa-2b as maintenance therapy in low-grade malignant lymphoma improves duration of remission and survival. Leuk Lymph 20:495-499, 1996
32. Unterhalt M, Herrmann R, Nahler M, et al: Significant prolongation of disease-free survival in advanced low-grade non-Hodgkin's lymphoma by interferon-alfa maintenance. Sixth International Conference on Malignant Lymphoma. Immunotherapy of non-Hodgkin's lymphoma. Satellite Symposium. Lugano, Switzerland, June 5-8, 1996, in Ann Oncol 7:229 (suppl 3)
33. Beelen D, Graeven U, Elmaagacli A, et al: Prolonged administration of interferon-alfa in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 85:2981-2990, 1995
34. Solal-Céligny P, Lepage E, Brousse N, et al: A doxorubicin-containing regimen with or without interferon alfa-2b in advanced follicular lymphomas. Final analysis of survival, toxicity and quality of life in the GELF trial. Thirty-eighth Annual Meeting of the American Society of Hematology, Orlando, FL December 6-10, 1996, in Blood 88:10 (abstr 1800; suppl 1)
35. Johnson PWM, Rohatiner AZ, Whelan CGA, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 13:140-147, 1995
36. Lister TA: The management of follicular lymphoma. Ann Oncol 2:131-135, 1991 (suppl 2)